Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “HOMATROPINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed2002

Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.

RATIONALE: The subjective, psychomotor, and physiological effects of prescription compounds containing the opioid hydrocodone have not been studied in a population of non-drug-abusing people who might be prescribed these compounds for cough or pain relief. OBJECTIVES: To characterize the effects of a hydrocodone combination product, Hycodan, which contains hydrocodone and a peripherally-acting anticholinergic, homatropine, in non-drug-abusing volunteers. METHODS: Eighteen volunteers participated in a crossover, double-blind study in which they received placebo; 5 mg hydrocodone/1.5 mg homatropine, 10 mg hydrocodone/3 mg homatropine, 20 mg hydrocodone/6 mg homatropine (all PO); 40 mg morphine (PO); and 2 mg lorazepam (PO). Measures were assessed before and for 300 min after drug administration. End-of-session and 24-h measures were taken to assess residual drug effects and overall subjects' assessment of the drug effects. RESULTS. Subjective effects of the hydrocodone/homatropine combination were dose-related, although the majority of statistically significant effects were limited to the highest dose combination tested. A combination of 20 mg hydrocodone/6 mg homatropine and morphine had a similar profile of subjective effects, which included both pleasant and unpleasant effects. Peak liking ratings were increased by 20 mg hydrocodone/6 mg homatropine and morphine, and trough ratings of liking (dislike) were lower in the 20 mg hydrocodone/6 mg homatropine condition, relative to the placebo condition. Post-session ratings of overall liking were not significant, either at the end of the session or 24 h later. Cognitive and psychomotor impairment were more marked with lorazepam than with hydrocodone/homatropine and morphine. Miosis and exophoria were increased in a dose-related manner by hydrocodone/homatropine. CONCLUSIONS: Hycodan at the highest dose tested had effects similar to that of a prototypic mu agonist, morphine. Both drugs produced pleasant (including drug liking) as well as unpleasant subjective effects. Post-session ratings of overall liking and "want to take drug again" were not significant.

Adult↗
PubMed1975

Role of the blood-brain barrier in the anticholinergic differential effects on LH and prolactin release in proestrous rats.

The effects of homatropine and atropine on plasma LH and prolactin (PRL) levels during the afternoon of pro-oestrus were investigated. Homatropine methylbromide was unable to block the spontaneous increase of LH but prevented the prolactin surge in pro-oestrous rats at doses of 450 and 700 mg/kg s.c. Atropine sulphate blocked both LH and PRL at doses of 450 and 700 mg/kg s.c. These two anticholinergics when injected into the 3rd ventricle (250 mug/rat) blocked the pro-oestrus increase of LH and inhibited PRL. Pharmacological experiments were performed in parallel and the injection of either homatropine or atropine (450 mg/kg s.c.) resulted in the abolishment of peripheral toxic signs induced by pilocarpine (50 mg/kg s.c.) whereas its central toxic signs were prevented by atropine but not by homatropine. Our findings suggest that the difference in action of systemic injections of atropine and homatropine on LH and PRL release is explained by a relatively low permeability of homatropine to the brain. Therefore, cholinergic LH-controlling mechanisms may be situated above the median eminence and those related to PRL placed outside the blood-brain barrier.

Animals↗